Many patients believe that dialysis or kidney transplant will be the only
choice when condition develop end-stage renal disease.However, we would like and
have to say it is wrong. Here we will talk about how to help ESRD patients avoid
dialysis effectively, hoping it can be helpful to you.
Though dialysis can help improve the life expectancy to a certain degree, it
cannot be counted as a long-term method. Various dialysis problems make more and
more patients want to stop dialysis treatment.
Dialysis carries several risks, although many can be avoided through proper
procedure and careful use of equipment. Risks associated with dialysis
include:
bleeding at the access site
low blood pressure
irregular heartbeat
infection
nausea
air bubbles in the blood
There are other long-term risks associated with dialysis. One of the most
common is called dialysis dementia, a neurological syndrome caused by aluminum
compounds in the dialysis fluid. Symptoms of dialysis dementia include seizures
and physical and speech problems.
If you experience any of these symptoms during dialysis treatment, notify
your doctor to discuss options and ways to lower your risks.
Patients should know that the only way to avoid dialysis is to make kidneys
work again by repairing kidney damage and recovering renal function. However,
nowdays it can be achieved with Chinese therapies in Shijiazhuang Kidney Disease
Hospital. Click Here to know why more and more foreign patients come to China for treatment. Have a question? Feel free to contact us.
Showing posts with label ESRD. Show all posts
Showing posts with label ESRD. Show all posts
Monday, July 20, 2015
Thursday, May 14, 2015
Minorities, Uninsured Lack Care of ESRD in Lupus Nephritis
No one knows what causes the disease. Your family history and things in your environment such as infections, viruses, toxic chemicals or pollutants (car fumes, factory smoke) may play a role in causing the disease. Wherever immune complexes are deposited, immunofluorescence staining is positive for complement and for IgG, IgA, and IgM in varying proportions. Epithelial cells may proliferate, forming crescents. Classification of lupus nephritis is based on histologic findings
In the United States, minorities and those who lack private insurance are less likely to receive adequate care for end-stage renal disease (ESRD) due to lupus nephritis (LN), according to research published online Feb. 18 in Arthritis & Rheumatology.
Laura C. Plantinga, Sc.M., of Emory University in Atlanta, and colleagues analyzed data for 6,594 patients initiating treatment for LN-ESRD, from July 2005 through September 2011, to assess factors associated with quality of care.
The researchers found that, compared with white patients, black and Hispanic patients were less likely to receive pre-ESRD care (odds ratios [ORs], 0.73 and 0.72, respectively) and less likely to be placed on the waitlist for kidney transplant (hazard ratios [HRs], 0.78 and 0.82, respectively).
Compared with patients with private insurance, patients with Medicaid (HR, 0.51) or without insurance (HR, 0.36) were less likely to be placed on the waitlist. Only 24% of patients had a permanent vascular access, and uninsured patients were even less likely to have placement of vascular access (OR, 0.62).
"LN-ESRD patients have suboptimal ESRD care, particularly with regard to vascular access placement," the authors write. "Minority race/ethnicity and lack of private insurance were associated with inadequate ESRD care."
kidneyhospitalabroad@hotmail.com
In the United States, minorities and those who lack private insurance are less likely to receive adequate care for end-stage renal disease (ESRD) due to lupus nephritis (LN), according to research published online Feb. 18 in Arthritis & Rheumatology.
Laura C. Plantinga, Sc.M., of Emory University in Atlanta, and colleagues analyzed data for 6,594 patients initiating treatment for LN-ESRD, from July 2005 through September 2011, to assess factors associated with quality of care.
The researchers found that, compared with white patients, black and Hispanic patients were less likely to receive pre-ESRD care (odds ratios [ORs], 0.73 and 0.72, respectively) and less likely to be placed on the waitlist for kidney transplant (hazard ratios [HRs], 0.78 and 0.82, respectively).
Compared with patients with private insurance, patients with Medicaid (HR, 0.51) or without insurance (HR, 0.36) were less likely to be placed on the waitlist. Only 24% of patients had a permanent vascular access, and uninsured patients were even less likely to have placement of vascular access (OR, 0.62).
"LN-ESRD patients have suboptimal ESRD care, particularly with regard to vascular access placement," the authors write. "Minority race/ethnicity and lack of private insurance were associated with inadequate ESRD care."
kidneyhospitalabroad@hotmail.com
Saturday, May 9, 2015
Phosphate Binders Cut Mortality, Up ESRD Risk
The ESRD composite rate payment system differs from most other prospective payment systems because there is a single product category to define the service Medicare is buying. Although different equipment, supplies, and labor are needed for hemodialysis and peritoneal dialysis, the current system does not differentiate payment based on dialysis method, location (home or incenter) or equipment used.
Phosphate binder use was associated with lower mortality risk but a higher risk of end-stage renal disease (ESRD) among patients with chronic kidney disease (CKD) and high phosphorus levels, according to study findings presented at the National Kidney Foundation's 2015 Spring Clinical Meetings in Dallas.
In a retrospective longitudinal cohort study, Ardeshir Khosraviani, MD, and colleagues at Kaiser Permanente Southern California compared phosphate binder use and non-use among 3,026 non-dialysis CKD patients with hyperphosphatemia (phosphorus levels 5.5 mg/dL or higher). Compared with patients who did not use phosphate binders, those who did had a 15% decreased mortality risk and a nearly 3-fold increased risk of ESRD, the investigators reported.
“These findings underscore the need to better understand whether earlier phosphorus management may impact morbidity and mortality in advanced CKD,” the authors concluded in a poster presentation. Of the 3,026 subjects, 596 used binders and 2,430 did not. Study subjects had a mean age was 65.5 years; 49% were female, 49% were white, 24% were Hispanic, 17.3% were black, and 8.5% were Asian. The binder group had higher rates of diabetes, hypertension, and coronary artery disease.
“Our study raises the question of whether earlier management and control of hyperphosphatemia in the CKD population with binder therapy may improve patient survival in terms of mortality prior to and after [transition to ESRD],” Dr. Khosraviani told Renal & Urology News.
He said he and his colleagues believe their study adds to the literature on the topic because it looked at a real-world practice environment using a large and heterogeneous CKD population, and the results provide insights into CKD mineral-bone management strategies as patients transition to ESRD.
kidneyhospitalabroad@hotmail.com
Phosphate binder use was associated with lower mortality risk but a higher risk of end-stage renal disease (ESRD) among patients with chronic kidney disease (CKD) and high phosphorus levels, according to study findings presented at the National Kidney Foundation's 2015 Spring Clinical Meetings in Dallas.
In a retrospective longitudinal cohort study, Ardeshir Khosraviani, MD, and colleagues at Kaiser Permanente Southern California compared phosphate binder use and non-use among 3,026 non-dialysis CKD patients with hyperphosphatemia (phosphorus levels 5.5 mg/dL or higher). Compared with patients who did not use phosphate binders, those who did had a 15% decreased mortality risk and a nearly 3-fold increased risk of ESRD, the investigators reported.
“These findings underscore the need to better understand whether earlier phosphorus management may impact morbidity and mortality in advanced CKD,” the authors concluded in a poster presentation. Of the 3,026 subjects, 596 used binders and 2,430 did not. Study subjects had a mean age was 65.5 years; 49% were female, 49% were white, 24% were Hispanic, 17.3% were black, and 8.5% were Asian. The binder group had higher rates of diabetes, hypertension, and coronary artery disease.
“Our study raises the question of whether earlier management and control of hyperphosphatemia in the CKD population with binder therapy may improve patient survival in terms of mortality prior to and after [transition to ESRD],” Dr. Khosraviani told Renal & Urology News.
He said he and his colleagues believe their study adds to the literature on the topic because it looked at a real-world practice environment using a large and heterogeneous CKD population, and the results provide insights into CKD mineral-bone management strategies as patients transition to ESRD.
kidneyhospitalabroad@hotmail.com
Monday, April 20, 2015
Partial Nephrectomy for Kidney Cancer Lowers ESRD Risk
End-stage renal disease is a condition in which the kidneys no longer function normally. The most common causes of ESRD in the U.S. are diabetes and high blood pressure. These conditions can affect your kidneys. Some problems you are born with, some reactions to medicines, and some injuries can also cause ESRD. They both need to fail for end-stage renal disease to develop.
Patients with renal cell carcinoma (RCC) are at lower risk of end-stage renal disease (ESRD) requiring renal replacement therapy if they undergo partial rather than radical nephrectomy, a new study suggests.
The population-based, retrospective cohort study of 11,937 RCC patients who underwent radical nephrectomy (RN) or partial nephrectomy (PN) during 1995–2010. Researchers divided subjects into an early cohort (those who had surgery from 1995–2002) and a modern cohort (those who had surgery from 2003–2010).
In the full cohort, the study revealed no significant association between type of surgery and ESRD rate, but PN was associated with a significant 52% decreased risk of chronic kidney disease (CKD).
In the modern cohort, PN recipients had a significant 56% decreased risk of ESRD requiring renal replacement therapy (RRT) compared with patients who underwent RN, after a median follow-up of 41 months, researchers led by Stanley A. Yap, MD, of the University of California Davis in Sacramento, reported online ahead of print in BJU International. In a propensity score analysis, which the investigators used to decrease bias and to control for differences between treatment groups, PN was associated with a significant 53% decreased risk of ESRD.
In the modern cohort, the RN and PN patients had a median time of progression to ESRD of 5 months and 16 months, respectively.
“Although it is well-known that RN is associated with more CKD than PN, we provide the first direct evidence that PN is associated with ESRD requiring renal replacement therapy than RN in a modern cohort of patients with RCC,” the authors concluded.
They also stated, “The distinction of a modern cohort is important, as it consists of patients that encompass a more accurate representation of current practice,” the investigators wrote. “During earlier years of the present cohort, PN had yet to gain widespread use and acceptance.”
Of the 11,937 patients in the full cohort, 9,830 (82%) and 2,107 (18%) underwent RN or PN, respectively. Overall, during the postoperative period, ESRD developed in 292 patients (2.5%). The group included 47 patients in the PN group (2.2%) compared with 245 patients in the RN group (2.5%). The mean time to progression to ESRD was 19 months and 38 months for patients in the RN and PN groups, respectively.
The early cohort included 4,297 RN patients and 360 PN patients, which had unadjusted rates of ESRD of 3.7% and 8.6%, respectively. The modern cohort included 5,484 (76%) and 1,746 (24%) patients who underwent RN and PN, respectively, and their unadjusted rates of ESRD were 1.6% and 0.9, respectively. If you have any questiosn you can send email to kidneyhospitalabroad@hotmail.com.
Patients with renal cell carcinoma (RCC) are at lower risk of end-stage renal disease (ESRD) requiring renal replacement therapy if they undergo partial rather than radical nephrectomy, a new study suggests.
The population-based, retrospective cohort study of 11,937 RCC patients who underwent radical nephrectomy (RN) or partial nephrectomy (PN) during 1995–2010. Researchers divided subjects into an early cohort (those who had surgery from 1995–2002) and a modern cohort (those who had surgery from 2003–2010).
In the full cohort, the study revealed no significant association between type of surgery and ESRD rate, but PN was associated with a significant 52% decreased risk of chronic kidney disease (CKD).
In the modern cohort, PN recipients had a significant 56% decreased risk of ESRD requiring renal replacement therapy (RRT) compared with patients who underwent RN, after a median follow-up of 41 months, researchers led by Stanley A. Yap, MD, of the University of California Davis in Sacramento, reported online ahead of print in BJU International. In a propensity score analysis, which the investigators used to decrease bias and to control for differences between treatment groups, PN was associated with a significant 53% decreased risk of ESRD.
In the modern cohort, the RN and PN patients had a median time of progression to ESRD of 5 months and 16 months, respectively.
“Although it is well-known that RN is associated with more CKD than PN, we provide the first direct evidence that PN is associated with ESRD requiring renal replacement therapy than RN in a modern cohort of patients with RCC,” the authors concluded.
They also stated, “The distinction of a modern cohort is important, as it consists of patients that encompass a more accurate representation of current practice,” the investigators wrote. “During earlier years of the present cohort, PN had yet to gain widespread use and acceptance.”
Of the 11,937 patients in the full cohort, 9,830 (82%) and 2,107 (18%) underwent RN or PN, respectively. Overall, during the postoperative period, ESRD developed in 292 patients (2.5%). The group included 47 patients in the PN group (2.2%) compared with 245 patients in the RN group (2.5%). The mean time to progression to ESRD was 19 months and 38 months for patients in the RN and PN groups, respectively.
The early cohort included 4,297 RN patients and 360 PN patients, which had unadjusted rates of ESRD of 3.7% and 8.6%, respectively. The modern cohort included 5,484 (76%) and 1,746 (24%) patients who underwent RN and PN, respectively, and their unadjusted rates of ESRD were 1.6% and 0.9, respectively. If you have any questiosn you can send email to kidneyhospitalabroad@hotmail.com.
Subscribe to:
Posts (Atom)